Free Trial

Leerink Partners' Rating of Larimar Therapeutics on 9/14/2026

On September 14, 2026, Leerink Partners updated its outlook on Larimar Therapeutics (NASDAQ:LRMR) with the action "Initiated Coverage", setting a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Leerink Partners

DateCompanyAction
11/9/2026
Veradermics, Incorporated stock logo
MANE
Veradermics
Boost Price Target
11/6/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Downgrade
11/5/2026
Incyte Corporation stock logo
INCY
Incyte
Lower Price Target
11/5/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Lower Price Target
11/5/2026
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
Boost Price Target
11/5/2026
Bruker Corporation stock logo
BRKR
Bruker
Boost Price Target
More Ratings From Leerink Partners